HRS-4642：控制 KRAS 的下一个难题。
HRS-4642: The next piece of the puzzle to keep KRAS in check.
发表日期：2024 Jul 08
作者：
Alejandra A Flores-Gómez, Matthias Drosten
来源：
CANCER CELL
摘要：
KRASG12D 是人类癌症中最常见的 KRAS 突变。在本期中，周等人。描述了一种新型 KRASG12D 抑制剂 HRS-4642，它在各种模型中显示出有效和选择性的抗肿瘤活性，并与蛋白酶体抑制剂具有协同作用。在正在进行的 1 期试验中也观察到了患者的反应。版权所有 © 2024 Elsevier Inc. 保留所有权利。
KRASG12D is the most frequent KRAS mutation in human cancer. In this issue, Zhou et al. describe a novel KRASG12D inhibitor, HRS-4642, that shows potent and selective anti-tumor activity across various models and synergizes with proteasome inhibitors. Responses have also been observed in patients during an ongoing phase 1 trial.Copyright © 2024 Elsevier Inc. All rights reserved.